Johnson & Johnson

Johnson & Johnson Reports Q1 2024 Results

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medtech, Patient, News, Pulmonary hypertension, Johnson & Johnson, Security (finance), Relapse, Press release, Esketamine, General surgery, Daratumumab, COVID-19, Pharmaceutical industry

First Quarter 2024 Segment Commentary:

Key Points: 
  • First Quarter 2024 Segment Commentary:
    Operational sales* reflected below excludes the impact of translational currency.
  • Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.
  • Notable New Announcements in the Quarter:
    The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
  • Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.

NorthStar Appoints Peter Pfreundschuh to Board of Managers

Retrieved on: 
Monday, April 15, 2024
Research, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, CFO, Cancer, LLP, NorthStar, Johnson & Johnson, Business development, Health technology, Business, Growth, CDMO, Rider University, Sucampo Pharmaceuticals, Patient, SCMP, Radiopharmaceutical, MBA, Therapy, Ernst & Young, Certified Public Accountant, AstraZeneca, Pharmaceutical industry

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024.

Key Points: 
  • NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024.
  • "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar.
  • “2024 and the next few years will be critical for NorthStar,” said Frank Scholz, NorthStar President and Chief Executive Officer.
  • I look forward to Pete joining the NorthStar Board.”

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Retrieved on: 
Wednesday, April 10, 2024
Research, Finance, Clinical Trials, Health Technology, Professional Services, Biotechnology, General Health, Health, Science, Other Science, Corporation, Risk, Johnson & Johnson, Neonatal Fc receptor, Data, Patient, Pharmaceutical industry

Rallybio is on track to initiate a Phase 2 dose confirmation study for RLYB212 in pregnant individuals at higher risk of alloimmunization and FNAIT in the second half of 2024.

Key Points: 
  • Rallybio is on track to initiate a Phase 2 dose confirmation study for RLYB212 in pregnant individuals at higher risk of alloimmunization and FNAIT in the second half of 2024.
  • Johnson & Johnson is conducting a Phase 3 study of nipocalimab, an investigational monoclonal antibody targeting FcRn, in pregnant individuals who are already alloimmunized.
  • “Our complementary approaches, if successful, would ensure that pregnant individuals at risk of developing FNAIT have a potential treatment option – regardless of their alloimmunization status.
  • Pregnant individuals who are already alloimmunized are not eligible for inclusion in Rallybio’s natural history study, nor for potential preventative treatment with Rallybio’s investigational therapeutic, RLYB212.

BioNJ Announces Lineup for BioPartnering Conference

Retrieved on: 
Thursday, April 25, 2024
Corporation, Ecosystem, Johnson & Johnson, Conference, Merck & Co., J. P. Morgan, Partner, Ferring Pharmaceuticals, Liberty Science Center, Osteonecrosis of the jaw, Sanofi, Teva Pharmaceuticals, Economic development, Health, Pharmaceutical industry

TRENTON, N.J., April 25, 2024 /PRNewswire/ -- BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City.

Key Points: 
  • TRENTON, N.J., April 25, 2024 /PRNewswire/ -- BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City.
  • The action-packed schedule is designed to create meaningful opportunities, grow the ecosystem and bolster medical innovation.
  • "The BioPartnering Conference is the ideal chance to discover innovative companies for investment portfolios," BioNJ President and CEO Debbie Hart noted.
  • "We have more than 90 companies from the life sciences, biotech, healthcare and digital health sectors presenting new innovations and technologies.

Prevent Blindness Declares May as First-ever Inherited Retinal Disease (IRD) Genetic Testing Awareness Month

Retrieved on: 
Wednesday, April 24, 2024
Education, Paratriathlon, University, Blood, Birth defect, Retina, RP, Social media, Diagnosis, Stargardt disease, Stargardt, Marketing, Strabismus, Genetic, Johnson & Johnson, Gene, Spark Therapeutics, Choroid, Research, Visual impairment, Genetic testing, Pediatric ophthalmology, Disease, Visual Science, Patient, Eye, Cone dystrophy, MBA, Vision, Student, Therapy, Organization, IRD, Pharmaceutical industry

CHICAGO, April 24, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has designated May as "Inherited Retinal Disease (IRD) Genetic Testing Awareness Month," expanding its previous IRD and Genetic Testing Awareness Week initiative. The group is providing a variety of tools to promote awareness and education for IRDs and the importance of genetic testing, including a free webinar, expert and patient videos, shareable social media graphics, and fact sheets in English and Spanish. IRD Genetic Testing Awareness Month is supported by funding from Johnson & Johnson, and Spark® Therapeutics.

Key Points: 
  • Prevent Blindness expands IRD and genetic testing awareness initiative to educate patients on various forms of IRDs, and the importance of genetic testing to confirm diagnosis and possible treatments.
  • CHICAGO, April 24, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has designated May as "Inherited Retinal Disease (IRD) Genetic Testing Awareness Month," expanding its previous IRD and Genetic Testing Awareness Week initiative.
  • ET, the National Center for Children's Vision and Eye Health at Prevent Blindness will be hosting the free webinar, " Pathway to Diagnosis: Genetic Testing for Inherited Retinal Diseases ."
  • To register for the "Pathway to Diagnosis: Genetic Testing for Inherited Retinal Diseases" webinar, visit PreventBlindness.org/IRD-webinar-2024.

GS1 Connect 2024 Agenda Offers Supply Chain Best Practices Across Retail, Grocery, Foodservice and Healthcare Industries

Retrieved on: 
Wednesday, April 24, 2024
EON, Supply, Target, Rothy's, The Coca-Cola Company, RFID, McDonald's, Fresenius (company), PepsiCo, Exhibition, Avery Dennison, Cardinal Health, Johnson & Johnson, Conference, Artificial intelligence, McKesson Corporation, Automation, GS1, Sustainability, Procter & Gamble, Bitly, Food, Salsify, SPS Commerce, Commerce, GS1 US, Digital, General Mills, Health, Management

EWING, NJ., April 24, 2024 /PRNewswire/ -- GS1 Connect 2024, the conference and exhibition hosted by GS1 US, will feature more than 300 leading companies that will share strategies for leveraging GS1 Standards to enable end-to-end supply chain visibility. Among the companies participating are Avery Dennison, BD, Bitly, Cardinal Health, Chick-fil-A, Dillard's, Fresenius Kabi, General Mills, Johnson & Johnson, Mars, McCormick & Company, McDonald's, McKesson, PepsiCo., Pfizer, Procter & Gamble, Target, Wegmans and more. The event will be held June 4-6, 2024, at the Orlando World Center Marriott in Orlando, Florida. To view the agenda, visit www.gs1us.org/gs1connect.

Key Points: 
  • The event will be held June 4-6, 2024, at the Orlando World Center Marriott in Orlando, Florida.
  • "GS1 Connect offers an unrivaled opportunity for industry members to learn about new developments and strategies that are driving visibility and optimization for an increasingly connected technology-driven world."
  • GS1 Connect is sponsored by 1WorldSync, Antares Vision Group, Avery Dennison, The Coca-Cola Company, Data Council + RIVIR, LSPedia, OPTEL, Salsify, SATO, Share-ify, SPS Commerce, Syndigo, and Trustwell.
  • To learn more about GS1 Connect 2024, visit www.gs1us.org/gs1connect .

Richa Goswami proposed as new Board member of EQT AB

Retrieved on: 
Wednesday, April 24, 2024
Standard Chartered, Marketing, Johnson & Johnson, FMCG, EQT AB, Digital, IPO, Committee, Fidelity International, Investor AB, Standard, EQT, HSBC, Knowledge

STOCKHOLM, April 24, 2024 /PRNewswire/ -- EQT AB (publ) today announced that the Nomination Committee proposes Richa Goswami as new Board member in EQT AB, bringing experience and expert knowledge within Brand & Marketing.

Key Points: 
  • STOCKHOLM, April 24, 2024 /PRNewswire/ -- EQT AB (publ) today announced that the Nomination Committee proposes Richa Goswami as new Board member in EQT AB, bringing experience and expert knowledge within Brand & Marketing.
  • Richa Goswami has in-depth knowledge and multi-sector experience from leading positions within Brand & Marketing across multiple geographies in the financial services and FMCG (fast-moving consumer goods) industry.
  • Conni Jonsson, Chairperson of the EQT AB Board, comments: "Johan is the longest serving Board member in EQT and his focus on long-term value creation and ownership has been much appreciated in the Board room.
  • The election of Richa Goswami as new Board member is subject to relevant regulatory approvals.

Top Biopharma Brands Reach Audiences 10x More Qualified with Veeva Crossix Prime Segments

Retrieved on: 
Tuesday, April 23, 2024
ROI, Johnson & Johnson, Veeva Systems, Patient, Privacy, Marketing

PLEASANTON, Calif., April 23, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 16 of the top 20 biopharmas are increasing media efficiency with Veeva Crossix Prime Segments, privacy-safe data helping life sciences brands reach highly-qualified health audiences. Since launching in April 2023, Veeva Crossix Prime Segments have helped top biopharmas reach consumers that are 10 times more qualified than standard health audience segments through digital media campaigns.

Key Points: 
  • Since launching in April 2023, Veeva Crossix Prime Segments have helped top biopharmas reach consumers that are 10 times more qualified than standard health audience segments through digital media campaigns.
  • Marketing teams can leverage Veeva Crossix Prime Segments to reach precise patient audiences and Veeva Crossix Reach Segments for broad awareness and ROI at scale.
  • "A diverse set of health brands are using Veeva Crossix Prime Segments to reach their most qualified audiences — from broad treatment categories to rare diseases," said Jessica Daigle, head of Veeva Crossix Audience Segments.
  • Veeva Crossix Prime Segments are custom-built to reach an advertiser's most qualified audience in a privacy-safe, HIPAA-compliant way.

Good Clean Love Embarks on a New Chapter of Growth and Innovation

Retrieved on: 
Tuesday, April 16, 2024
Education, Woman, Health, Johnson & Johnson, Love, Research, Life, Demers, All Ages, Overalls, Biotechnology, Birth control

EUGENE, Ore., April 16, 2024 /PRNewswire/ -- Good Clean Love, the trailblazing brand of natural and organic sexual and vaginal health products, is thrilled to announce a transformative phase in its journey. Under new CEO Brenda Demers, a seasoned executive with 20 years of experience from Unilever and Johnson & Johnson, the brand is poised for a new era of expansion and looks to solve real health problems for women through innovative products that support the vaginal microbiome.

Key Points: 
  • Founded two decades ago in Wendy Strgar's kitchen, Good Clean Love has always been a force for innovation, integrity, and education on the essential role the vaginal microbiome plays in women's reproductive and overall health.
  • "Collaborating with science-backed brands within the health and wellness realm and affecting tangible change in the lives of women is my passion," stated Brenda Demers, CEO of Good Clean Love.
  • Demers' enthusiasm for helping women live and love well will be instrumental in driving Good Clean Love's mission of giving anyone with a vagina agency over their sexual and reproductive health.
  • Good Clean Love is proud to be leading the charge in providing innovative solutions that empower women at every stage of life.

DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT JLABS @ SAN FRANCISCO

Retrieved on: 
Monday, April 15, 2024
Lung, FDA, Johnson & Johnson, Biomarker, Patient, Iris, Pharmaceutical industry

By expanding footprint within the US, Respiree aims to deepen its relationships and networks within the pharma and life science sector.

Key Points: 
  • By expanding footprint within the US, Respiree aims to deepen its relationships and networks within the pharma and life science sector.
  • Respiree was formerly a company at JLABS in Singapore.
  • Respiree's team also aims to extend the development of its novel digital therapeutics pipeline to incorporate real-world pharma evidence.
  • "We are very proud and excited to be continuing our JLABS journey, first as alumni of JLABS @ Shanghai, then JLABS Singapore and now to JLABS @ South San Francisco.